投资界(ID:pedaily2012)5月14日消息,据凯易国际律师事务所发布,其代表领先生物医药风险投资公司礼来亚洲基金(LAV)完成其第七期美元生命科学基金礼来亚洲第七期基金(LAV Fund VII, L.P.)的募集。该基金以封顶金额最终交割,获得来自全球各地的各类机构投资者的踊跃认购,包括主权财富基金、养老金、捐赠基金、大家族办公室、大型企业和母基金。不仅如此,就在今年3月31日,上海...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.